nodes	percent_of_prediction	percent_of_DWPC	metapath
Milnacipran—Eye disorder—Methylprednisolone—ankylosing spondylitis	0.00418	0.00418	CcSEcCtD
Milnacipran—Cardiac disorder—Methylprednisolone—ankylosing spondylitis	0.00416	0.00416	CcSEcCtD
Milnacipran—Neutropenia—Prednisone—ankylosing spondylitis	0.00414	0.00414	CcSEcCtD
Milnacipran—Irritability—Methotrexate—ankylosing spondylitis	0.00409	0.00409	CcSEcCtD
Milnacipran—Erectile dysfunction—Prednisone—ankylosing spondylitis	0.00408	0.00408	CcSEcCtD
Milnacipran—Angiopathy—Methylprednisolone—ankylosing spondylitis	0.00406	0.00406	CcSEcCtD
Milnacipran—Hallucination—Betamethasone—ankylosing spondylitis	0.00405	0.00405	CcSEcCtD
Milnacipran—Hallucination—Dexamethasone—ankylosing spondylitis	0.00405	0.00405	CcSEcCtD
Milnacipran—Mediastinal disorder—Methylprednisolone—ankylosing spondylitis	0.00404	0.00404	CcSEcCtD
Milnacipran—Weight decreased—Prednisone—ankylosing spondylitis	0.00401	0.00401	CcSEcCtD
Milnacipran—Vision blurred—Prednisolone—ankylosing spondylitis	0.004	0.004	CcSEcCtD
Milnacipran—Liver function test abnormal—Methotrexate—ankylosing spondylitis	0.00396	0.00396	CcSEcCtD
Milnacipran—Mental disorder—Methylprednisolone—ankylosing spondylitis	0.00392	0.00392	CcSEcCtD
Milnacipran—Malnutrition—Methylprednisolone—ankylosing spondylitis	0.0039	0.0039	CcSEcCtD
Milnacipran—Breast disorder—Methotrexate—ankylosing spondylitis	0.00387	0.00387	CcSEcCtD
Milnacipran—Dysgeusia—Triamcinolone—ankylosing spondylitis	0.00383	0.00383	CcSEcCtD
Milnacipran—Syncope—Prednisolone—ankylosing spondylitis	0.00381	0.00381	CcSEcCtD
Milnacipran—Eye disorder—Dexamethasone—ankylosing spondylitis	0.00381	0.00381	CcSEcCtD
Milnacipran—Eye disorder—Betamethasone—ankylosing spondylitis	0.00381	0.00381	CcSEcCtD
Milnacipran—Loss of consciousness—Prednisolone—ankylosing spondylitis	0.00373	0.00373	CcSEcCtD
Milnacipran—Angiopathy—Betamethasone—ankylosing spondylitis	0.00369	0.00369	CcSEcCtD
Milnacipran—Angiopathy—Dexamethasone—ankylosing spondylitis	0.00369	0.00369	CcSEcCtD
Milnacipran—Convulsion—Prednisolone—ankylosing spondylitis	0.00368	0.00368	CcSEcCtD
Milnacipran—Hypertension—Prednisolone—ankylosing spondylitis	0.00367	0.00367	CcSEcCtD
Milnacipran—Hallucination—Prednisone—ankylosing spondylitis	0.00353	0.00353	CcSEcCtD
Milnacipran—Syncope—Triamcinolone—ankylosing spondylitis	0.0035	0.0035	CcSEcCtD
Milnacipran—Syncope—Methylprednisolone—ankylosing spondylitis	0.0035	0.0035	CcSEcCtD
Milnacipran—Connective tissue disorder—Prednisone—ankylosing spondylitis	0.00348	0.00348	CcSEcCtD
Milnacipran—Dysuria—Methotrexate—ankylosing spondylitis	0.00346	0.00346	CcSEcCtD
Milnacipran—Neutropenia—Methotrexate—ankylosing spondylitis	0.00346	0.00346	CcSEcCtD
Milnacipran—Upper respiratory tract infection—Methotrexate—ankylosing spondylitis	0.00344	0.00344	CcSEcCtD
Milnacipran—Loss of consciousness—Triamcinolone—ankylosing spondylitis	0.00343	0.00343	CcSEcCtD
Milnacipran—Loss of consciousness—Methylprednisolone—ankylosing spondylitis	0.00343	0.00343	CcSEcCtD
Milnacipran—Shock—Prednisolone—ankylosing spondylitis	0.00341	0.00341	CcSEcCtD
Milnacipran—Erectile dysfunction—Methotrexate—ankylosing spondylitis	0.00341	0.00341	CcSEcCtD
Milnacipran—Convulsion—Triamcinolone—ankylosing spondylitis	0.00338	0.00338	CcSEcCtD
Milnacipran—Tachycardia—Prednisolone—ankylosing spondylitis	0.00338	0.00338	CcSEcCtD
Milnacipran—Convulsion—Methylprednisolone—ankylosing spondylitis	0.00338	0.00338	CcSEcCtD
Milnacipran—Hypertension—Triamcinolone—ankylosing spondylitis	0.00337	0.00337	CcSEcCtD
Milnacipran—Hypertension—Methylprednisolone—ankylosing spondylitis	0.00337	0.00337	CcSEcCtD
Milnacipran—Hyperhidrosis—Prednisolone—ankylosing spondylitis	0.00335	0.00335	CcSEcCtD
Milnacipran—Eye disorder—Prednisone—ankylosing spondylitis	0.00331	0.00331	CcSEcCtD
Milnacipran—Anxiety—Methylprednisolone—ankylosing spondylitis	0.00331	0.00331	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.0033	0.0033	CcSEcCtD
Milnacipran—Flushing—Prednisone—ankylosing spondylitis	0.00329	0.00329	CcSEcCtD
Milnacipran—Stevens-Johnson syndrome—Methotrexate—ankylosing spondylitis	0.00327	0.00327	CcSEcCtD
Milnacipran—Dry mouth—Triamcinolone—ankylosing spondylitis	0.00325	0.00325	CcSEcCtD
Milnacipran—Angiopathy—Prednisone—ankylosing spondylitis	0.00322	0.00322	CcSEcCtD
Milnacipran—Syncope—Dexamethasone—ankylosing spondylitis	0.00318	0.00318	CcSEcCtD
Milnacipran—Syncope—Betamethasone—ankylosing spondylitis	0.00318	0.00318	CcSEcCtD
Milnacipran—Infection—Triamcinolone—ankylosing spondylitis	0.00317	0.00317	CcSEcCtD
Milnacipran—Infection—Methylprednisolone—ankylosing spondylitis	0.00316	0.00316	CcSEcCtD
Milnacipran—Haematuria—Methotrexate—ankylosing spondylitis	0.00315	0.00315	CcSEcCtD
Milnacipran—Shock—Triamcinolone—ankylosing spondylitis	0.00314	0.00314	CcSEcCtD
Milnacipran—Insomnia—Prednisolone—ankylosing spondylitis	0.00314	0.00314	CcSEcCtD
Milnacipran—Shock—Methylprednisolone—ankylosing spondylitis	0.00313	0.00313	CcSEcCtD
Milnacipran—Hepatobiliary disease—Methotrexate—ankylosing spondylitis	0.00312	0.00312	CcSEcCtD
Milnacipran—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.00312	0.00312	CcSEcCtD
Milnacipran—Loss of consciousness—Betamethasone—ankylosing spondylitis	0.00312	0.00312	CcSEcCtD
Milnacipran—Loss of consciousness—Dexamethasone—ankylosing spondylitis	0.00312	0.00312	CcSEcCtD
Milnacipran—Paraesthesia—Prednisolone—ankylosing spondylitis	0.00311	0.00311	CcSEcCtD
Milnacipran—Tachycardia—Triamcinolone—ankylosing spondylitis	0.00311	0.00311	CcSEcCtD
Milnacipran—Mental disorder—Prednisone—ankylosing spondylitis	0.00311	0.00311	CcSEcCtD
Milnacipran—Tachycardia—Methylprednisolone—ankylosing spondylitis	0.0031	0.0031	CcSEcCtD
Milnacipran—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.00309	0.00309	CcSEcCtD
Milnacipran—Malnutrition—Prednisone—ankylosing spondylitis	0.00309	0.00309	CcSEcCtD
Milnacipran—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	0.00308	0.00308	CcSEcCtD
Milnacipran—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	0.00308	0.00308	CcSEcCtD
Milnacipran—Convulsion—Dexamethasone—ankylosing spondylitis	0.00307	0.00307	CcSEcCtD
Milnacipran—Convulsion—Betamethasone—ankylosing spondylitis	0.00307	0.00307	CcSEcCtD
Milnacipran—Hypertension—Dexamethasone—ankylosing spondylitis	0.00306	0.00306	CcSEcCtD
Milnacipran—Hypertension—Betamethasone—ankylosing spondylitis	0.00306	0.00306	CcSEcCtD
Milnacipran—Anxiety—Betamethasone—ankylosing spondylitis	0.00301	0.00301	CcSEcCtD
Milnacipran—Anxiety—Dexamethasone—ankylosing spondylitis	0.00301	0.00301	CcSEcCtD
Milnacipran—Hypotension—Methylprednisolone—ankylosing spondylitis	0.00297	0.00297	CcSEcCtD
Milnacipran—Hepatitis—Methotrexate—ankylosing spondylitis	0.00296	0.00296	CcSEcCtD
Milnacipran—Urinary tract disorder—Methotrexate—ankylosing spondylitis	0.00293	0.00293	CcSEcCtD
Milnacipran—Vision blurred—Prednisone—ankylosing spondylitis	0.00291	0.00291	CcSEcCtD
Milnacipran—Urethral disorder—Methotrexate—ankylosing spondylitis	0.00291	0.00291	CcSEcCtD
Milnacipran—Insomnia—Triamcinolone—ankylosing spondylitis	0.00288	0.00288	CcSEcCtD
Milnacipran—Insomnia—Methylprednisolone—ankylosing spondylitis	0.00288	0.00288	CcSEcCtD
Milnacipran—Infection—Betamethasone—ankylosing spondylitis	0.00287	0.00287	CcSEcCtD
Milnacipran—Infection—Dexamethasone—ankylosing spondylitis	0.00287	0.00287	CcSEcCtD
Milnacipran—Paraesthesia—Triamcinolone—ankylosing spondylitis	0.00286	0.00286	CcSEcCtD
Milnacipran—Paraesthesia—Methylprednisolone—ankylosing spondylitis	0.00286	0.00286	CcSEcCtD
Milnacipran—Shock—Betamethasone—ankylosing spondylitis	0.00285	0.00285	CcSEcCtD
Milnacipran—Shock—Dexamethasone—ankylosing spondylitis	0.00285	0.00285	CcSEcCtD
Milnacipran—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.00284	0.00284	CcSEcCtD
Milnacipran—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.00284	0.00284	CcSEcCtD
Milnacipran—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.00284	0.00284	CcSEcCtD
Milnacipran—Agitation—Prednisone—ankylosing spondylitis	0.00284	0.00284	CcSEcCtD
Milnacipran—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	0.00283	0.00283	CcSEcCtD
Milnacipran—Thrombocytopenia—Betamethasone—ankylosing spondylitis	0.00283	0.00283	CcSEcCtD
Milnacipran—Tachycardia—Dexamethasone—ankylosing spondylitis	0.00282	0.00282	CcSEcCtD
Milnacipran—Tachycardia—Betamethasone—ankylosing spondylitis	0.00282	0.00282	CcSEcCtD
Milnacipran—Dyspepsia—Triamcinolone—ankylosing spondylitis	0.00281	0.00281	CcSEcCtD
Milnacipran—Erythema multiforme—Methotrexate—ankylosing spondylitis	0.0028	0.0028	CcSEcCtD
Milnacipran—Dyspepsia—Methylprednisolone—ankylosing spondylitis	0.0028	0.0028	CcSEcCtD
Milnacipran—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	0.0028	0.0028	CcSEcCtD
Milnacipran—Hyperhidrosis—Betamethasone—ankylosing spondylitis	0.0028	0.0028	CcSEcCtD
Milnacipran—Eye disorder—Methotrexate—ankylosing spondylitis	0.00277	0.00277	CcSEcCtD
Milnacipran—Syncope—Prednisone—ankylosing spondylitis	0.00277	0.00277	CcSEcCtD
Milnacipran—Anorexia—Dexamethasone—ankylosing spondylitis	0.00276	0.00276	CcSEcCtD
Milnacipran—Anorexia—Betamethasone—ankylosing spondylitis	0.00276	0.00276	CcSEcCtD
Milnacipran—Urticaria—Prednisolone—ankylosing spondylitis	0.00275	0.00275	CcSEcCtD
Milnacipran—Cardiac disorder—Methotrexate—ankylosing spondylitis	0.00275	0.00275	CcSEcCtD
Milnacipran—Fatigue—Triamcinolone—ankylosing spondylitis	0.00275	0.00275	CcSEcCtD
Milnacipran—Fatigue—Methylprednisolone—ankylosing spondylitis	0.00274	0.00274	CcSEcCtD
Milnacipran—Loss of consciousness—Prednisone—ankylosing spondylitis	0.00271	0.00271	CcSEcCtD
Milnacipran—Hypotension—Dexamethasone—ankylosing spondylitis	0.0027	0.0027	CcSEcCtD
Milnacipran—Hypotension—Betamethasone—ankylosing spondylitis	0.0027	0.0027	CcSEcCtD
Milnacipran—Angiopathy—Methotrexate—ankylosing spondylitis	0.00269	0.00269	CcSEcCtD
Milnacipran—Convulsion—Prednisone—ankylosing spondylitis	0.00267	0.00267	CcSEcCtD
Milnacipran—Mediastinal disorder—Methotrexate—ankylosing spondylitis	0.00267	0.00267	CcSEcCtD
Milnacipran—Hypertension—Prednisone—ankylosing spondylitis	0.00267	0.00267	CcSEcCtD
Milnacipran—Chills—Methotrexate—ankylosing spondylitis	0.00266	0.00266	CcSEcCtD
Milnacipran—Anxiety—Prednisone—ankylosing spondylitis	0.00262	0.00262	CcSEcCtD
Milnacipran—Insomnia—Betamethasone—ankylosing spondylitis	0.00262	0.00262	CcSEcCtD
Milnacipran—Insomnia—Dexamethasone—ankylosing spondylitis	0.00262	0.00262	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.00261	0.00261	CcSEcCtD
Milnacipran—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	0.0026	0.0026	CcSEcCtD
Milnacipran—Paraesthesia—Betamethasone—ankylosing spondylitis	0.0026	0.0026	CcSEcCtD
Milnacipran—Paraesthesia—Dexamethasone—ankylosing spondylitis	0.0026	0.0026	CcSEcCtD
Milnacipran—Mental disorder—Methotrexate—ankylosing spondylitis	0.0026	0.0026	CcSEcCtD
Milnacipran—Malnutrition—Methotrexate—ankylosing spondylitis	0.00258	0.00258	CcSEcCtD
Milnacipran—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.00255	0.00255	CcSEcCtD
Milnacipran—Dyspepsia—Dexamethasone—ankylosing spondylitis	0.00255	0.00255	CcSEcCtD
Milnacipran—Dyspepsia—Betamethasone—ankylosing spondylitis	0.00255	0.00255	CcSEcCtD
Milnacipran—Urticaria—Triamcinolone—ankylosing spondylitis	0.00253	0.00253	CcSEcCtD
Milnacipran—Urticaria—Methylprednisolone—ankylosing spondylitis	0.00253	0.00253	CcSEcCtD
Milnacipran—Dysgeusia—Methotrexate—ankylosing spondylitis	0.00253	0.00253	CcSEcCtD
Milnacipran—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.00252	0.00252	CcSEcCtD
Milnacipran—Abdominal pain—Methylprednisolone—ankylosing spondylitis	0.00251	0.00251	CcSEcCtD
Milnacipran—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.00251	0.00251	CcSEcCtD
Milnacipran—Decreased appetite—Betamethasone—ankylosing spondylitis	0.00251	0.00251	CcSEcCtD
Milnacipran—Infection—Prednisone—ankylosing spondylitis	0.0025	0.0025	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.0025	0.0025	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.0025	0.0025	CcSEcCtD
Milnacipran—Fatigue—Dexamethasone—ankylosing spondylitis	0.00249	0.00249	CcSEcCtD
Milnacipran—Fatigue—Betamethasone—ankylosing spondylitis	0.00249	0.00249	CcSEcCtD
Milnacipran—Shock—Prednisone—ankylosing spondylitis	0.00248	0.00248	CcSEcCtD
Milnacipran—Nervous system disorder—Prednisone—ankylosing spondylitis	0.00247	0.00247	CcSEcCtD
Milnacipran—Tachycardia—Prednisone—ankylosing spondylitis	0.00246	0.00246	CcSEcCtD
Milnacipran—Skin disorder—Prednisone—ankylosing spondylitis	0.00245	0.00245	CcSEcCtD
Milnacipran—Hyperhidrosis—Prednisone—ankylosing spondylitis	0.00244	0.00244	CcSEcCtD
Milnacipran—Vision blurred—Methotrexate—ankylosing spondylitis	0.00243	0.00243	CcSEcCtD
Milnacipran—Anorexia—Prednisone—ankylosing spondylitis	0.0024	0.0024	CcSEcCtD
Milnacipran—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	0.00237	0.00237	CcSEcCtD
Milnacipran—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	0.00237	0.00237	CcSEcCtD
Milnacipran—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.00235	0.00235	CcSEcCtD
Milnacipran—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.00234	0.00234	CcSEcCtD
Milnacipran—Leukopenia—Methotrexate—ankylosing spondylitis	0.00231	0.00231	CcSEcCtD
Milnacipran—Urticaria—Betamethasone—ankylosing spondylitis	0.0023	0.0023	CcSEcCtD
Milnacipran—Urticaria—Dexamethasone—ankylosing spondylitis	0.0023	0.0023	CcSEcCtD
Milnacipran—Dizziness—Prednisolone—ankylosing spondylitis	0.00229	0.00229	CcSEcCtD
Milnacipran—Asthenia—Triamcinolone—ankylosing spondylitis	0.00229	0.00229	CcSEcCtD
Milnacipran—Abdominal pain—Betamethasone—ankylosing spondylitis	0.00229	0.00229	CcSEcCtD
Milnacipran—Body temperature increased—Betamethasone—ankylosing spondylitis	0.00229	0.00229	CcSEcCtD
Milnacipran—Abdominal pain—Dexamethasone—ankylosing spondylitis	0.00229	0.00229	CcSEcCtD
Milnacipran—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.00229	0.00229	CcSEcCtD
Milnacipran—Asthenia—Methylprednisolone—ankylosing spondylitis	0.00228	0.00228	CcSEcCtD
Milnacipran—Insomnia—Prednisone—ankylosing spondylitis	0.00228	0.00228	CcSEcCtD
Milnacipran—Paraesthesia—Prednisone—ankylosing spondylitis	0.00226	0.00226	CcSEcCtD
Milnacipran—Pruritus—Triamcinolone—ankylosing spondylitis	0.00226	0.00226	CcSEcCtD
Milnacipran—Pruritus—Methylprednisolone—ankylosing spondylitis	0.00225	0.00225	CcSEcCtD
Milnacipran—Convulsion—Methotrexate—ankylosing spondylitis	0.00224	0.00224	CcSEcCtD
Milnacipran—Dyspepsia—Prednisone—ankylosing spondylitis	0.00222	0.00222	CcSEcCtD
Milnacipran—Chest pain—Methotrexate—ankylosing spondylitis	0.0022	0.0022	CcSEcCtD
Milnacipran—Decreased appetite—Prednisone—ankylosing spondylitis	0.00219	0.00219	CcSEcCtD
Milnacipran—Rash—Prednisolone—ankylosing spondylitis	0.00219	0.00219	CcSEcCtD
Milnacipran—Dermatitis—Prednisolone—ankylosing spondylitis	0.00218	0.00218	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.00218	0.00218	CcSEcCtD
Milnacipran—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.00218	0.00218	CcSEcCtD
Milnacipran—Fatigue—Prednisone—ankylosing spondylitis	0.00217	0.00217	CcSEcCtD
Milnacipran—Headache—Prednisolone—ankylosing spondylitis	0.00217	0.00217	CcSEcCtD
Milnacipran—Constipation—Prednisone—ankylosing spondylitis	0.00215	0.00215	CcSEcCtD
Milnacipran—Dizziness—Triamcinolone—ankylosing spondylitis	0.00211	0.00211	CcSEcCtD
Milnacipran—Dizziness—Methylprednisolone—ankylosing spondylitis	0.0021	0.0021	CcSEcCtD
Milnacipran—Infection—Methotrexate—ankylosing spondylitis	0.00209	0.00209	CcSEcCtD
Milnacipran—Asthenia—Dexamethasone—ankylosing spondylitis	0.00208	0.00208	CcSEcCtD
Milnacipran—Asthenia—Betamethasone—ankylosing spondylitis	0.00208	0.00208	CcSEcCtD
Milnacipran—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.00206	0.00206	CcSEcCtD
Milnacipran—Thrombocytopenia—Methotrexate—ankylosing spondylitis	0.00206	0.00206	CcSEcCtD
Milnacipran—Gastrointestinal pain—Prednisone—ankylosing spondylitis	0.00206	0.00206	CcSEcCtD
Milnacipran—Nausea—Prednisolone—ankylosing spondylitis	0.00206	0.00206	CcSEcCtD
Milnacipran—Pruritus—Betamethasone—ankylosing spondylitis	0.00205	0.00205	CcSEcCtD
Milnacipran—Pruritus—Dexamethasone—ankylosing spondylitis	0.00205	0.00205	CcSEcCtD
Milnacipran—Skin disorder—Methotrexate—ankylosing spondylitis	0.00205	0.00205	CcSEcCtD
Milnacipran—Hyperhidrosis—Methotrexate—ankylosing spondylitis	0.00204	0.00204	CcSEcCtD
Milnacipran—Vomiting—Triamcinolone—ankylosing spondylitis	0.00203	0.00203	CcSEcCtD
Milnacipran—Vomiting—Methylprednisolone—ankylosing spondylitis	0.00202	0.00202	CcSEcCtD
Milnacipran—Rash—Triamcinolone—ankylosing spondylitis	0.00201	0.00201	CcSEcCtD
Milnacipran—Dermatitis—Triamcinolone—ankylosing spondylitis	0.00201	0.00201	CcSEcCtD
Milnacipran—Anorexia—Methotrexate—ankylosing spondylitis	0.00201	0.00201	CcSEcCtD
Milnacipran—Rash—Methylprednisolone—ankylosing spondylitis	0.00201	0.00201	CcSEcCtD
Milnacipran—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.002	0.002	CcSEcCtD
Milnacipran—Urticaria—Prednisone—ankylosing spondylitis	0.002	0.002	CcSEcCtD
Milnacipran—Headache—Triamcinolone—ankylosing spondylitis	0.002	0.002	CcSEcCtD
Milnacipran—Headache—Methylprednisolone—ankylosing spondylitis	0.00199	0.00199	CcSEcCtD
Milnacipran—Body temperature increased—Prednisone—ankylosing spondylitis	0.00199	0.00199	CcSEcCtD
Milnacipran—Abdominal pain—Prednisone—ankylosing spondylitis	0.00199	0.00199	CcSEcCtD
Milnacipran—Diarrhoea—Betamethasone—ankylosing spondylitis	0.00198	0.00198	CcSEcCtD
Milnacipran—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.00198	0.00198	CcSEcCtD
Milnacipran—Hypotension—Methotrexate—ankylosing spondylitis	0.00197	0.00197	CcSEcCtD
Milnacipran—Dizziness—Betamethasone—ankylosing spondylitis	0.00191	0.00191	CcSEcCtD
Milnacipran—Dizziness—Dexamethasone—ankylosing spondylitis	0.00191	0.00191	CcSEcCtD
Milnacipran—Insomnia—Methotrexate—ankylosing spondylitis	0.0019	0.0019	CcSEcCtD
Milnacipran—Nausea—Triamcinolone—ankylosing spondylitis	0.00189	0.00189	CcSEcCtD
Milnacipran—Paraesthesia—Methotrexate—ankylosing spondylitis	0.00189	0.00189	CcSEcCtD
Milnacipran—Nausea—Methylprednisolone—ankylosing spondylitis	0.00189	0.00189	CcSEcCtD
Milnacipran—Dyspnoea—Methotrexate—ankylosing spondylitis	0.00188	0.00188	CcSEcCtD
Milnacipran—Somnolence—Methotrexate—ankylosing spondylitis	0.00187	0.00187	CcSEcCtD
Milnacipran—Hypersensitivity—Prednisone—ankylosing spondylitis	0.00186	0.00186	CcSEcCtD
Milnacipran—Dyspepsia—Methotrexate—ankylosing spondylitis	0.00185	0.00185	CcSEcCtD
Milnacipran—Vomiting—Betamethasone—ankylosing spondylitis	0.00184	0.00184	CcSEcCtD
Milnacipran—Vomiting—Dexamethasone—ankylosing spondylitis	0.00184	0.00184	CcSEcCtD
Milnacipran—Decreased appetite—Methotrexate—ankylosing spondylitis	0.00183	0.00183	CcSEcCtD
Milnacipran—Rash—Dexamethasone—ankylosing spondylitis	0.00182	0.00182	CcSEcCtD
Milnacipran—Rash—Betamethasone—ankylosing spondylitis	0.00182	0.00182	CcSEcCtD
Milnacipran—Dermatitis—Dexamethasone—ankylosing spondylitis	0.00182	0.00182	CcSEcCtD
Milnacipran—Dermatitis—Betamethasone—ankylosing spondylitis	0.00182	0.00182	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.00182	0.00182	CcSEcCtD
Milnacipran—Fatigue—Methotrexate—ankylosing spondylitis	0.00182	0.00182	CcSEcCtD
Milnacipran—Headache—Dexamethasone—ankylosing spondylitis	0.00181	0.00181	CcSEcCtD
Milnacipran—Headache—Betamethasone—ankylosing spondylitis	0.00181	0.00181	CcSEcCtD
Milnacipran—Asthenia—Prednisone—ankylosing spondylitis	0.00181	0.00181	CcSEcCtD
Milnacipran—Pruritus—Prednisone—ankylosing spondylitis	0.00178	0.00178	CcSEcCtD
Milnacipran—Diarrhoea—Prednisone—ankylosing spondylitis	0.00172	0.00172	CcSEcCtD
Milnacipran—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	0.00172	0.00172	CcSEcCtD
Milnacipran—Nausea—Betamethasone—ankylosing spondylitis	0.00172	0.00172	CcSEcCtD
Milnacipran—Nausea—Dexamethasone—ankylosing spondylitis	0.00172	0.00172	CcSEcCtD
Milnacipran—Urticaria—Methotrexate—ankylosing spondylitis	0.00167	0.00167	CcSEcCtD
Milnacipran—Dizziness—Prednisone—ankylosing spondylitis	0.00167	0.00167	CcSEcCtD
Milnacipran—Abdominal pain—Methotrexate—ankylosing spondylitis	0.00166	0.00166	CcSEcCtD
Milnacipran—Body temperature increased—Methotrexate—ankylosing spondylitis	0.00166	0.00166	CcSEcCtD
Milnacipran—Vomiting—Prednisone—ankylosing spondylitis	0.0016	0.0016	CcSEcCtD
Milnacipran—Rash—Prednisone—ankylosing spondylitis	0.00159	0.00159	CcSEcCtD
Milnacipran—Dermatitis—Prednisone—ankylosing spondylitis	0.00159	0.00159	CcSEcCtD
Milnacipran—Headache—Prednisone—ankylosing spondylitis	0.00158	0.00158	CcSEcCtD
Milnacipran—Hypersensitivity—Methotrexate—ankylosing spondylitis	0.00155	0.00155	CcSEcCtD
Milnacipran—Asthenia—Methotrexate—ankylosing spondylitis	0.00151	0.00151	CcSEcCtD
Milnacipran—Nausea—Prednisone—ankylosing spondylitis	0.0015	0.0015	CcSEcCtD
Milnacipran—Pruritus—Methotrexate—ankylosing spondylitis	0.00149	0.00149	CcSEcCtD
Milnacipran—Diarrhoea—Methotrexate—ankylosing spondylitis	0.00144	0.00144	CcSEcCtD
Milnacipran—Dizziness—Methotrexate—ankylosing spondylitis	0.00139	0.00139	CcSEcCtD
Milnacipran—Vomiting—Methotrexate—ankylosing spondylitis	0.00134	0.00134	CcSEcCtD
Milnacipran—Rash—Methotrexate—ankylosing spondylitis	0.00133	0.00133	CcSEcCtD
Milnacipran—Dermatitis—Methotrexate—ankylosing spondylitis	0.00133	0.00133	CcSEcCtD
Milnacipran—Headache—Methotrexate—ankylosing spondylitis	0.00132	0.00132	CcSEcCtD
Milnacipran—Nausea—Methotrexate—ankylosing spondylitis	0.00125	0.00125	CcSEcCtD
